首页 | 本学科首页   官方微博 | 高级检索  
     


Interferon therapy for chronic hepatitis B
Authors:Asselah Tarik  Lada Olivier  Moucari Rami  Martinot Michèle  Boyer Nathalie  Marcellin Patrick
Affiliation:1. Cancer Research Center of Lyon (CRCL), Lyon 69008, France;2. INSERM U1052, CNRS UMR-5286, Lyon 69008, France;3. University of Lyon, Université Claude-Bernard (UCBL), 69008 Lyon, France;4. Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Trogerstrasse 30, 81675 Munich, Germany;5. German Center for Infection Research (DZIF), Munich Site, Germany;1. Replicor, Montreal, QC, Canada;2. Department of Infectious Diseases, State University of Medicine and Pharmacy ‘Nicolae Testemitanu’, Chișinău, Moldova;3. Toma Ciorbă Hospital of Infectious Diseases, Chișinău, Moldova;4. National Genetics Institute, Los Angeles, CA, USA;5. Laboratoire de Microbiologie Clinique, Centre National de référence des hépatites B, C et Delta, Hôpitaux Universitaires de Paris Seine-Saint-Denis, Université Sorbonne Paris Cité, Paris, France;6. Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany;7. Institute for Virology, Technical University of Munich, Munich, Germany;1. Auckland Clinical Studies, Auckland, New Zealand;2. School of Biological Sciences, and Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand;3. Gilead Sciences, Inc., Foster City, CA, USA;1. I. Department of Medicine, Center for Internal Medicine, University Medical Center Hamburg-Eppendorf, Germany;2. Department of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;3. German Center for Infection Research, Hamburg-Lübeck-Borstel Partner Site, Germany;4. IFI Institute for Interdisciplinary Medicine at Asklepios Clinic St. Georg, Hamburg, Germany;5. Hoffmann-La Roche, Inc., Nutley, NJ, USA;1. The Chinese University of Hong Kong, Hong Kong;2. Toronto General Hospital, Toronto, ON, Canada;3. Queen Mary Hospital, Hong Kong;4. Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;5. Chiayi Christian Hospital, Chiayi, Taiwan;6. Chung-Ang University Hospital, Seoul, South Korea;7. Alice Ho Miu Ling Nethersole Hospital, Hong Kong;8. Toronto Centre for Liver Disease, Toronto, ON, Canada;9. Institute of Post Graduate Medical Education and Research, Kolkata, India;10. Princess Margaret Hospital, Hong Kong;11. Surat Institute of Medical Sciences, Surat, Gujarat, India;12. Auckland Clinical Studies, Auckland, New Zealand;13. Gilead Sciences, Foster City, CA, USA;14. Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;15. All India Institute of Medical Sciences, New Delhi, Delhi, India;p. Kings College Hospital, London, UK;1. Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California;2. Division of Translational Research, Taipei Veterans General Hospital, Taipei City, Taiwan;3. Genomics Research Center, Academia Sinica, Taipei, Taiwan;4. Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan;5. Department of Hepatology, Toranomon Hospital, Takatsu-ku, Kawasaki, Japan;6. San Jose Gastroenterology, San Jose, California;7. Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Republic of Korea;8. Hepatology Center, Department of Internal Medicine and Biomedical Research Center, Bundang Jesaeng General Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea;9. Department of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of China;10. Liver Unit, Hospital Universitari Vall d’Hebron and Ciberehd del Instituto Carlos III, Barcelona, Spain;11. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Barcelona, Spain;12. Liver Unit, Division of Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain;13. Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand;14. Department of Gastroenterology, Clinic Fundeni Institute, Bucharest, Romania;15. Faculty of Medicine and Public Health, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Thailand;16. Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand;17. Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China;18. Palo Alto Medical Foundation, Mountain View Division, Palo Alto, California;19. Chinese Hospital, San Francisco, California;20. School of Nursing, University of California, San Francisco, California;21. Kaohsiung Medical University, Kaohsiung, Taiwan;22. Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan;23. Research Institute for Hepatology, Toranomon Hospital, Takatsu-ku, Kawasaki, Japan;24. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan;25. Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan;26. College of Public Health, China Medical University, Taichung, Taiwan
Abstract:This article summarizes the results obtained with interferon alfa and pegylated interferon alfa, as monotherapy and in combination with lamivudine, in the treatment of chronic hepatitis B.
Keywords:
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号